Answers are grounded in this paper and cite their sources.
Expert review reveals pathways for directly inhibiting c-Myc in cancer models, highlighting strategies like Omomyc miniaturization to enable clinical translation.
c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
No takes yet. Share an insight, caveat, or question.
Madden et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: